SITE004-0166

SITE004 (DEU) › SITE004-0166

SITE004-0166

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-03-12

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Nausea — outcome: UNKNOWN; onset 2023-01-04 (study day 101); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.